Digital Pathology Round-Up – April 2024

Cranfield, UK, 30th April 2024, Written by Imogen Fitt – 

Hello everyone, this month has been very busy with lots of exciting announcements!✨

I’ve also been writing the first deliverable of our digital pathology market intelligence service, a #USCAP24 show report, which offers an in depth analysis of all the news and trends at this years conference. This report is useful if:

• You’re a Healthtech vendor wondering how recent news will impact your business
• You’re an investor looking to understand key market dynamics and how they will impact your target vendors
• You’re a start-up in stealth mode looking to familiarise yourself with the market and learn best how to launch

Click the following link to learn more, or drop me a note and we can set up some time to discuss how our market intelligence can benefit you and your company. 😁

Below, here’s the DP community news for April rounded up:

1. First off, Nucleai announced it was collaborating withGoPath Diagnostics to develop some digital pathology tools combining Nucleai’s spatial biology and AI expertise with GoPath’s data and lab services. The tools developed will have applications across clinical trials and diagnostics, including developing prognostic algorithms! AI spatial biomarkers are an exciting new area of research that is gaining quite a bit of attention recently. Whilst techniques like multiplex imaging might take a while to make it into clinical practice, Nucleai’s platform ingests data on H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics.
2. Charles River Laboratories and Deciphex have launched ‘Patholytix Foresight’ an AI-Powered Decision Support Tool for Toxicologic Pathology. The tool incorporates organ-based lesion classifiers and was built on Patholytix 4.0, a research IMS. This news comes after Aiforia Technologies‘ announcement earlier in the year, which along the same vein involved the commercial launch of a co-developed algorithm. Could this be a new trend AI vendors use to expand their workflows quickly? Message me to learn more!
3. Deciphex also announced this month that it had entered into an agreement with Novartis to develop a suite of AI tools for preclinical pathology assessments in drug discovery and development, specifically toxicological and efficacy studies. Details on specifically what the suite entailed were more sparse (likely because Novartis didn’t want to give its competitors a heads up, but this news further confirms how pharma is doubling down on the use of DP AI across business lines.
4. AIxMed, Inc. and CorePLUS have announced a partnership where the latter will pilot the former’s urine cytology workflow. It will be research use only at first, but another good sign that labs in the US are increasingly willing to explore how AI can augment practices – and another signal that 2024 is also the year of #digitalcytology!
5. PathAI and Google partnered at Bio-IT World to provide the PathAI IMS on the Google Cloud infrastructure. Google’s been more active in the DP space recently, hosting its own talks at last years’ Pathology Visions, where Google’s Healthcare API DICOM Store was presented. The company’s strategy was presented as focusing on building and partnering to provide labs access to digital pathology software in order to scale scanning volume, storage and computation.
6. Scopio Labs received FDA clearance for its ‘Digital Bone Marrow Aspirate Application’. Cytology making headlines again! Keep an eye on Signify Research Ltd‘s LinkedIn page for more of an analysis on this soon….
7. Aiforia Technologies signed a contract with a veterinary health company in the US (unnamed in the press release), and in addition this month Proscia signed a contract with ‘SpecialtyVETPATH’. Two announcements in one month, does this indicate a surge in the veterinary market? I look forward to learning more as I begin renewing the research for our core update next!
8. PT. PathGen Diagnostik Teknologi raised funding from East Ventures and Royal Indonesia Group. The company specialises in molecular testing solutions and provides a DP AI platform, and will reportedly use the funds for R&D and market expansion. Good to hear some examples of successful rounds raised.
9. Indica Labs announced another partnership with Molecular Instruments centred around co-marketing compatibility between ‘AI-Powered quantitative image analysis with HCR(TM) RNA-ISH’. The press release saw Indica Labs cite a ‘growing need’ from its research customers for ‘RNA-ISH assays that maintain cellular morphology’. Co-marketing agreements can be useful, but may also result in very little extra revenue generated for each company so it’s important to view these kinds of announcements with some level of scepticism. Both companies now need to invest in collaborating to upsell into complementary customer segments in order to derive success. Hopefully there’ll be more information to come!
10. Finally, Sectra and Leica Biosystems announced FDA clearance for Sectra’s IMS on the GT450 DX scanner. As I shared yesterday, of particular note is that the clearance is for both the native SVS standard and DICOM. Demand for DICOM is slowly building in the US, and whilst use in clinical practice may be low today milestones like this are a sure signal that the market is heading in that direction.

That’s all for this month! If you’d like to discuss any of the pieces in more detail, do reach out. I’d be interested to know if more insight would be valuable for my readers!

Related Research

Digital Pathology Market Intelligence Service – World – 2024

Signify Research’s Market Intelligence Service provides a rolling 12-month coverage of the global Digital Pathology market. The service is composed of five deliverables and is designed to help you:

• Inform product investment and business strategy
• Evaluate the ever-changing competitive landscape to assess the impact of associations and select potential partners
• Acquire a holistic view of the nuances between different pathology research and clinical markets
• Understand adjacent markets such as enterprise imaging, laboratory information systems and the influence these will have on Digital Pathology

For any further questions or samples of the service contents, do drop me a note. 😊

About Imogen Fitt

Imogen joined Signify in 2018 as part of the Healthcare IT team. She holds a 1st class Biomedical Sciences degree from the University of Warwick where her studies included molecular biology and pharmacology. Since joining the team Imogen has studied the medical imaging software and hardware markets and is now expanding Signify Research’s Diagnostics and Lifesciences coverage.

About the Diagnostics and Lifesciences Team

The Diagnostics and Lifesciences team provides market intelligence and detailed insights on the multiple healthcare technology markets where the clinical world intersects with the preclinical. Our areas of coverage include digital pathology, laboratory information systems, clinical Real-World Data (cRWD) platforms, oncology information systems, tumour board software, oncology decision support software and radiotherapy IT. Each report provides a data-centric and global outlook of its markets with granular country-level insights. Our research process blends primary data collected from in-depth interviews with healthcare professionals and technology vendors, to provide a balanced and objective view of the market.

About Signify Research

Signify Research provides healthtech market intelligence powered by data that you can trust. We blend insights collected from in-depth interviews with technology vendors and healthcare professionals with sales data reported to us by leading vendors to provide a complete and balanced view of the market trends. Our coverage areas are Medical Imaging, Clinical Care, Digital Health, Diagnostic and Lifesciences and Healthcare IT.

Clients worldwide rely on direct access to our expert Analysts for their opinions on the latest market trends and developments. Our market analysis reports and subscriptions provide data-driven insights which business leaders use to guide strategic decisions. We also offer custom research services for clients who need information that can’t be obtained from our off-the-shelf research products or who require market intelligence tailored to their specific needs.

More Information

To find out more:
E: enquiries@signifyresearch.net
T: +44 (0) 1234 986111
www.signifyresearch.net